USA News Group
Commentary
Issued on behalf of BioVaxys Technology
Corp.
VANCOUVER, BC, July 29,
2024 /CNW/ -- USA News Group – How and what we eat is
always changing. But for more and more people, the options to eat
are drastically being reduced, due to rising amounts of food
allergies. According to Food Allergy Research & Education
(FARE), food allergy prevalence among children has been
surging, up by 50% between 1997 and 2011, and up again by another
50% between 2007 and 2021. Research analysts at Spherical
Insights projects strong growth in the Global Allergy Treatment
Market, growing at a CAGR of 9.27% to nearly US$14 billion by 2033. Now that food allergies
affect more than 7% of American children, researchers are exploring
different treatment approaches to tackle this serious and
potentially lucrative issue, including BioVaxys Technology
Corp. (CSE: BIOV) (OTCQB: BVAXF), Roche Holding AG
(OTCQX: RHHBY), Novartis AG (NYSE: NVS), Neogen
Corporation (NASDAQ: NEOG), and Thermo Fisher Scientific
Inc. (NYSE: TMO).
Earlier this year, clinical-stage biotech company BioVaxys
Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) made a splash by
strategically acquiring a broad clinical development pipeline
that included the advanced immunotherapeutics platform technology
DPX™. BioVaxys specifically targeted DPX™ as a potential
gamechanger in improved mRNA vaccines, multivalent viral vaccines,
immune system diseases, and more important to the topic of food
allergies, vaccines for desensitizing immune response for peanut
allergies.
DPX™ is a proprietary lipid-based delivery platform with no
aqueous component that can be formulated with a range of packaged
antigens, proteins, peptides, mRNA, or small molecules. Its
unique "no release" mechanism of action allows antigen presenting
cells (APCs) to be attracted to the injection site, facilitating a
robust and sustained immune response.
Since the acquisition, BioVaxys has moved forward with a
successful fundraising, and another recently announced private
placement later in July. But now it appears that the vision of
where DPX™ is coming into view, with the company signing a binding
letter of intent (LOI) to develop DPX™-based vaccines therapy to
treat or alleviate the potentially life-threatening risk of certain
food allergies, namely those triggered by exposure to peanut/tree
nuts or eggs.
In order to achieve this, BioVaxys is set to partner with
AP Visionaires, Inc. of Ontario
(APVI), whom they'll be conducting a study in collaboration
with The Schroeder Allergy and Immunology Research Institute
(SAIRI) at McMaster
University in Ontario—a new institute that consolidates
clinicians, scientists, and data specialists in a "one-stop shop"
to research the causes of life-threatening allergies and develop
new treatments.
Under the terms of the Agreement, BioVaxys will provide
funding for the study to APVI, which has a collaboration in
place with SAIRI to evaluate in animal models the robustness
of DPX™ protection and evaluate whether DPX™ transforms the
underlying immunopathology of food allergy. Afterards,
BioVaxys will retain all intellectual property rights to any
resulting product.
"Our ability to tackle this unmet medical need is directly
attributable to the immune educating capability and highly flexible
antigen loading capacity of our DPX™ platform," said Kenneth Kovan, President & Chief Operating
Officer of BioVaxys. "With the DPX™ platform already the
backbone of multiple BioVaxys clinical programs in oncology
and infectious disease, we see a staggering opportunity for
continued expansion into other novel DPX-formulations with
polynucleotides, peptides, proteins, virus-like articles, and small
molecules."
The market for peanut allergies seems to be growing quite
rapidly. According to Global Market Insights, the Peanut
Allergy Treatment Market is anticipated to grow at 12.1%
CAGR from 2024 to 2032. Researchers at Grand View
Research echo the sentiment, projecting this market to reach
US$1.01 billion by 2030, growing at
11.82% CAGR throughout that period.
Earlier this year, the FDA granted approval to
Xolair from Roche Holding AG (OTCQX: RHHBY) and
Novartis AG (NYSE: NVS), becoming the first medicine
to reduce allergic reactions that can occur with accidental
exposure to certain foods for people ages 1 year and older.
While not designed to allow patients to freely eat these foods
they're allergic to, the therapy helps them to avoid severe
reactions, such as anaphylaxis—which is a life-threatening reaction
that can happen immediately as the immune system releases chemicals
that can cause the body to go into shock.
Xolair is specifically approved for people with IgE-mediated
food allergies, a classification that includes 160 foods, the most
common of which are peanuts, milk, eggs, wheat, soy and tree
nuts.
"Many people with food allergies and their loved ones live in
constant fear of accidentally coming into contact with the food
they are allergic to and the life-threatening allergic reaction,"
said Reshema Kemps-Polanco, U.S.
Chief Commercial Officer for Novartis in a release. "This
approval, which comes 20 years after the first approval for this
medicine [for allergenic asthma], shows that we never stop
innovating to make a meaningful difference for patients living with
immunological conditions."
While treating allergies directly will hopefully save more
lives, the importance of detecting allergens in food processing and
diagnosing food allergies before a dangerous potential anaphylaxis
event occurs.
For example, late last year Neogen Corporation (NASDAQ:
NEOG), experts in food safety and processing, announced that it had
released its Veratox VIP assay for the detection of walnut,
the third assay in its Veratox VIP line of enhanced quantitative
ELISA products. The innovative quantitative test demonstrated
excellent specificity down to 0.15 ppm walnut protein, one of the
lowest detection concentrations for an ELISA kit, and utilizes a
best-in-class 30-minute time-to-result and ready-to-use
reagents.
"As tree nuts remain one of the most common allergens, it is
incredibly important that we are providing solutions that make it
easier for producers to detect potential contamination, and
strengthen their allergen control plans," said John Adent, President and CEO of Neogen.
"Given the highly sensitive nature of the new Veratox VIP for
Walnut assay, producers can be confident in Neogen's strong
commitment to food safety and quality."
Last year, Thermo Fisher Scientific Inc. (NYSE: TMO)
widened availability of its ImmunoCAP™ Specific IgE tests
to patients at all Kroger Health The Little Clinic LLC
locations, through a blood draw taken on site.
The ImmunoCAP-specific IgE regional respiratory profiles require
only one blood draw analyzed at an offsite clinical laboratory. The
tests are not new to the industry and are backed by 50+ years of
research and development. According to Future Market
Insights the IgE Allergy Blood Tests Market is expected to rise
at a 5.2% CAGR to US$50 billion in
2033.
"Discovering the actual cause of allergy-like symptoms is vital
to empowering patients to address their condition from a
preventative medicine standpoint, allowing a more personalized
management plan," said Gary
Falcetano, scientific affairs manager at Thermo Fisher
Scientific. "Adding trusted and accurate ImmunoCAP testing to
all The Little Clinic locations will enable clinicians to
help many more patients get the answers they need to proactively
manage their health."
Since 2019, Thermo Fisher
has been promoting a blood test designed to support the diagnosis
of peanut allergies, after receiving 510(k) clearance from the
FDA in 2018, by developing a range of ImmunoCAP in vitro
quantitative assays to help healthcare professionals determine
whether patients are allergic to particular components of peanuts
or suffer from cross-reactivity.
Article Source:
https://biotech-insider.com/the-phoenix-of-biotech-how-a-6m-junior-just-swooped-into-a-potential-billion-dollar-opportunity/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for BioVaxys Technology Corp. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of BioVaxys Technology Corp., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
BioVaxys Technology Corp. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of BioVaxys Technology Corp.at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
BioVaxys Technology Corp.; this is a paid advertisement, we
currently own shares of BioVaxys Technology Corp. and will buy and
sell shares of the company in the open market, or through private
placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
View original
content:https://www.prnewswire.com/news-releases/exploring-new-frontiers-in-food-allergy-treatments-market-set-for-14b-growth-302209055.html
SOURCE USA News Group